- Axogen continues posting double-digit growth in volumes against 2019 levels despite trauma, breast recon, and oral-maxillofacial procedures still well below pre-pandemic levels.
- COVID-19 infections are definitely a short-term risk and an impediment to sales and training efforts, but usage among trained surgeons and core accounts continues to grow nicely.
- Data in 2022 and 2023 should accelerate adoption, helping smooth the path to 20% or better revenue growth with products that provide demonstrable clinical and quality of life benefits.
- Axogen shares look undervalued below the mid-$20s.
For further details see:
Axogen: Renewed Covid-19 Worries Hitting, But The Growth Story Is Very Appealing